Alizé Pharma Group announced today the acquisition from EUSA of a preclinical recombinant L-asparaginase program
The Alizé Pharma Group, a group of private biopharmaceutical companies based in Lyon, focused on metabolic disorders and cancer, announced today that it has closed the acquisition from EUSA Pharma of a preclinical recombinant L-asparaginase program for the treatment of acute lymphoblastic leukaemia and other haematological malignancies.
Within this agreement, EUSA Pharma was granted an option to license back the product.
Creation of Alizé Pharma II SAS
The Alizé Pharma Group also announced that it created Alizé Pharma II SAS and that it raised 1.1 M Euros from Octalfa SAS and CEMA Inc., its historical investors, for the purpose of the transaction.
The proceeds of the financing are being used for the upfront payment of the acquisition and to reach value-creating R&D milestones within the next 12 months.
Further info
Download the Alizé Pharma press release (107 Ko)
Website: www.alz-pharma.com
